ACP6 (acid phosphatase 6, lysophosphatidic) is a mitochondrial lipid phosphatase that hydrolyzes lysophosphatidic acid (LPA) to monoacylglycerol and phosphate, with optimal activity toward medium-chain fatty acid LPA species 1. The enzyme possesses a conserved Rossmann-fold-like body domain and substrate-binding pocket suitable for accommodating LPA, functioning as a catalytically active monomer 1. ACP6 plays a critical regulatory role in multiple cancers through opposing mechanisms. In ovarian cancer, mutant p53 suppresses ACP6 expression, leading to LPA accumulation and enhanced focal adhesion signaling that promotes proliferation, migration, and invasion 2. Conversely, in endometrial and hepatocellular carcinomas, ACP6 is overexpressed and promotes tumor progression via PI3K/AKT pathway activation 34. In esophageal squamous cell carcinoma, low ACP6 expression correlates with aggressive invasion and poor prognosis, suggesting tumor-suppressive functions 5. These contrasting roles indicate ACP6 functions contextually in cancer biology, potentially through LPA-dependent and independent mechanisms. Beyond cancer, ACP6 has been identified as a candidate gene in cerebral visual impairment 6. ACP6 represents a promising therapeutic target, with nitidine chloride shown to suppress ACP6 expression in hepatocellular carcinoma models 4.